Troponin Blood Test May Minimize Hospitalization
By HospiMedica International staff writers Posted on 20 Oct 2015 |
A new study shows that using a high-sensitivity cardiac troponin I (cTnI) assay can halve the number of people admitted to hospital with a suspected myocardial infarction (MI).
Researchers at the University of Edinburgh (United Kingdom), Hennepin County Medical Center (Minneapolis, MN, USA), and other institutions conducted a prospective cohort study of 6,304 patients with suspected acute coronary syndrome presenting to four secondary and tertiary care hospitals in Scotland. The researchers measured plasma cTnI concentrations at presentation and evaluated the negative predictive value of a range of troponin concentrations for MI, subsequent MI, or cardiac death at 30 days.
The results showed that low plasma cTnI concentrations could identify two-thirds of patients at very low risk of cardiac events who could be discharged from hospital. In patients without MI at presentation, troponin concentrations were less than 5 ng/L in 61% of the patients, with a negative predictive value of 99.6% consistent across groups stratified by age, sex, risk factors, and previous cardiovascular disease. At one year, these patients had a lower risk of MI and cardiac death than did those with a cTnI concentration of 5 ng/L or more. The study was published on October 7, 2015, in the Lancet.
“Our study shows that low heart troponin concentrations identify up to two-thirds of patients who are at very low risk of heart attack and could be safely discharged,” said lead author Anoop Shah, MD, and colleagues of the BHF Centre for Cardiovascular Science at the University of Edinburgh. “These findings could dramatically reduce unnecessary hospital admissions and potentially save the National Health Service millions, as it can reduce unnecessary emergency admissions.”
Cardiac troponin T (cTnT) and troponin I (cTnI) are regulatory proteins that control the calcium mediated interaction between actin and myosin. The cardiac forms of these regulatory proteins are coded by specific genes and theoretically have the potential of being unique to the myocardium. The measurement of serum cTnI and cTnT is superior in terms of sensitivity and specificity to cardiac muscle enzyme measurements in the identification of cardiac muscle damage, currently accepted as the standard biochemical marker for the diagnosis of MI.
Related Links:
University of Edinburgh
Hennepin County Medical Center
Researchers at the University of Edinburgh (United Kingdom), Hennepin County Medical Center (Minneapolis, MN, USA), and other institutions conducted a prospective cohort study of 6,304 patients with suspected acute coronary syndrome presenting to four secondary and tertiary care hospitals in Scotland. The researchers measured plasma cTnI concentrations at presentation and evaluated the negative predictive value of a range of troponin concentrations for MI, subsequent MI, or cardiac death at 30 days.
The results showed that low plasma cTnI concentrations could identify two-thirds of patients at very low risk of cardiac events who could be discharged from hospital. In patients without MI at presentation, troponin concentrations were less than 5 ng/L in 61% of the patients, with a negative predictive value of 99.6% consistent across groups stratified by age, sex, risk factors, and previous cardiovascular disease. At one year, these patients had a lower risk of MI and cardiac death than did those with a cTnI concentration of 5 ng/L or more. The study was published on October 7, 2015, in the Lancet.
“Our study shows that low heart troponin concentrations identify up to two-thirds of patients who are at very low risk of heart attack and could be safely discharged,” said lead author Anoop Shah, MD, and colleagues of the BHF Centre for Cardiovascular Science at the University of Edinburgh. “These findings could dramatically reduce unnecessary hospital admissions and potentially save the National Health Service millions, as it can reduce unnecessary emergency admissions.”
Cardiac troponin T (cTnT) and troponin I (cTnI) are regulatory proteins that control the calcium mediated interaction between actin and myosin. The cardiac forms of these regulatory proteins are coded by specific genes and theoretically have the potential of being unique to the myocardium. The measurement of serum cTnI and cTnT is superior in terms of sensitivity and specificity to cardiac muscle enzyme measurements in the identification of cardiac muscle damage, currently accepted as the standard biochemical marker for the diagnosis of MI.
Related Links:
University of Edinburgh
Hennepin County Medical Center
Latest Critical Care News
- Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients
- Peptide-Based Hydrogels Repair Damaged Organs and Tissues On-The-Spot
- One-Hour Endoscopic Procedure Could Eliminate Need for Insulin for Type 2 Diabetes
- AI Can Prioritize Emergency Department Patients Requiring Urgent Treatment
- AI to Improve Diagnosis of Atrial Fibrillation
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure